Shares of Genomic Health Inc. (NASDAQ:GHDX) dropped 2.3% during trading on Monday . The stock traded as low as $27.09 and last traded at $27.11, with a volume of 76,649 shares. The stock had previously closed at $27.76.

GHDX has been the subject of several analyst reports. Zacks Investment Research downgraded Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday, July 5th. Leerink Swann reissued a “buy” rating on shares of Genomic Health in a research note on Tuesday, June 21st. Finally, Canaccord Genuity raised Genomic Health from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a research note on Wednesday, June 1st. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $33.50.

The stock has a 50 day moving average price of $26.64 and a 200-day moving average price of $27.02. The stock’s market capitalization is $903.29 million.

Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings data on Wednesday, May 4th. The company reported ($0.19) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.05. The firm had revenue of $80.89 million for the quarter, compared to the consensus estimate of $78.12 million. The business’s revenue was up 18.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.30) earnings per share. On average, analysts predict that Genomic Health Inc. will post ($0.45) EPS for the current fiscal year.

In other news, insider Steven Shak sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 4th. The stock was sold at an average price of $25.43, for a total value of $254,300.00. Following the sale, the insider now directly owns 336,383 shares of the company’s stock, valued at approximately $8,554,219.69. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO G Bradley Cole sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $27.60, for a total value of $138,000.00. Following the completion of the sale, the chief operating officer now directly owns 39,970 shares in the company, valued at $1,103,172. The disclosure for this sale can be found here.

Several hedge funds recently modified their holdings of GHDX. Marshall Wace LLP bought a new stake in shares of Genomic Health during the fourth quarter worth approximately $6,097,000. ProShare Advisors LLC boosted its stake in shares of Genomic Health by 8.6% in the fourth quarter. ProShare Advisors LLC now owns 28,759 shares of the company’s stock worth $1,012,000 after buying an additional 2,287 shares in the last quarter. Russell Frank Co boosted its stake in shares of Genomic Health by 327.4% in the fourth quarter. Russell Frank Co now owns 99,754 shares of the company’s stock worth $3,517,000 after buying an additional 76,416 shares in the last quarter. EAM Investors LLC bought a new stake in shares of Genomic Health during the fourth quarter worth approximately $1,055,000. Finally, California State Teachers Retirement System boosted its stake in shares of Genomic Health by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 32,989 shares of the company’s stock worth $1,161,000 after buying an additional 600 shares in the last quarter.

Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.